Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Conductor Daniel Barenboim says he has been diagnosed with Parkinson's disease. The 82-year-old issued a statement Thursday ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Doctors and researchers say ping pong can help slow Parkinson's disease. The South County Recreation Center in Bixby hosts Ping Pong Parkinson on Friday nights, offering a place for those with the ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...